Elevation of Stearoyl‐Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum
Movement Disorders · 2026-08 · 41 (8) · 2178-2183
DOI: 10.1002/mds.70264 ↗Abstract
Abstract Background Emerging evidence indicates that dysregulation of monounsaturated fatty acids (MUFAs), synthesized by the enzyme stearoyl‐coenzyme A desaturase (SCD), impacts on α‐synuclein pathology in the Parkinson's disease (PD) brain. Objective The objective of this study was to analyze SCD and MUFA‐enriched lipids in the periphery of patients with sporadic PD compared with healthy control subjects. Methods Serum SCD protein was quantified using enzyme‐linked immunosorbent assay in patients with PD (n = 40) and control subjects (n = 41). Lipidomic profiling was performed using liquid chromatography–mass spectrometry and LipidSearch software. Statistical analyses included Mann–Whitney U tests and Welch's t tests with false discovery rate (FDR) correction. Results SCD levels were higher in PD (mean = 1702 pg/ml) compared with control subjects (1158 pg/ml; P = 2.2 × 10 −4 ; Cohen's d = 0.73). Lipidomics showed elevated MUFA content in four lipid classes: methylphosphatidylcholine, phosphatidylcholine, dihexosylceramide, and triglycerides (FDR < 0.05). Conclusions Increased SCD and MUFA‐enriched lipids indicate altered membrane and sphingolipid metabolism in PD, consistent with central disease pathology, that present a potential for novel biomarker development for PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
EUVIMED